Indian Heart Journal (Mar 2017)

Premature coronary artery disease in India: coronary artery disease in the young (CADY) registry

  • S.S. Iyengar,
  • Rajiv Gupta,
  • Sandhya Ravi,
  • Saral Thangam,
  • Thomas Alexander,
  • C.N. Manjunath,
  • R. Keshava,
  • C.B. Patil,
  • Annie Sheela,
  • J.P.S. Sawhney

DOI
https://doi.org/10.1016/j.ihj.2016.09.009
Journal volume & issue
Vol. 69, no. 2
pp. 211 – 216

Abstract

Read online

Background: Coronary artery disease (CAD) occurs at younger age in India but only a limited number of studies have evaluated risk factors and management status. This is a multisite observational registry to assess risk factors and treatment patterns in young patients presenting with acute coronary syndrome (ACS) and stable ischemic heart disease (IHD). Methods: We recruited 997 young patients (men <55, women <65 y) presenting with ACS or stable IHD successively at 22 centers across India. Details of baseline risk factors and management status were obtained. Descriptive statistics are reported. Results: Mean age of participants was 49.1 ± 8y, 72% were men and 68% had ACS. Family history of CAD was in 50%, diabetes 44%, hypertension 49%, history of dyslipidemia 11%, smoking/tobacco use 39%, and sedentary habits in 20%. 1.3% had “possible familial hypercholesterolemia”. Metabolic risk factors (high BMI, diabetes and hypertension) were significantly greater in women (p < 0.01). Women were older at diagnosis of CAD and presented more often with non-ST elevation ACS. In the study cohort antiplatelet use was in 85%, beta-blockers 38%, statins 63% and ACE inhibitors/ARBs in 41% while in ACS patients it was 80.5%, 54.6%, 80.8% and 40.8%, respectively. 35.9% patients underwent percutaneous coronary intervention while coronary bypass surgery was performed in 10.4%. Conclusions: Conventional risk factors including family history continue to play a pivotal role in premature CAD in Indians. Women have more of metabolic risk factors, present at a later age and have non-ST elevation ACS more often. There is a need to focus on improving use of evidence-based drug therapies and interventions.

Keywords